HeartBeam Inc. (NASDAQ: BEAT) has announced the launch of a pilot study focused on evaluating its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and inadequate blood flow and oxygen supply to tissue, or ischemia. The study represents a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (“MCT”) markets, according to the company.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam has launched this new pilot study designed to evaluate its technology.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could provide clinicians with critical data to diagnose and manage coronary artery disease more effectively.”
The HeartBeam patch aims to address a key limitation of current ambulatory monitoring devices, which typically cannot detect ischemia. By enabling on-demand 12-lead ECG recordings, the patch could offer a non-invasive, patient-friendly method for continuous monitoring outside of clinical settings. This could lead to earlier detection of cardiac issues, potentially preventing heart attacks and other serious events.
The pilot study is expected to provide initial data on the patch’s ability to accurately detect ischemia in patients with known or suspected coronary artery disease. Positive results could pave the way for larger clinical trials and eventual regulatory clearance, bringing the device closer to market. The company intends to leverage its existing technology and expertise to develop a product that meets the needs of both patients and healthcare providers.
HeartBeam’s focus on this technology comes at a time when the global burden of cardiovascular disease is increasing. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, with an estimated 17.9 million lives lost each year. Innovations in remote monitoring and diagnostics are critical to improving outcomes and reducing healthcare costs associated with these conditions.
For more information about HeartBeam and its latest developments, visit the company’s newsroom at https://nnw.fm/BEAT.
